Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension

Amresh Shrivastava1, Megan E Johnston2, Nilesh Shah3, Marco Innamorati4, Larry Stitt5, Meghana Thakar3, David Lester6, Maurizio Pompili4,71Silver Mind Hospital and Mental Health Foundation of India, Mumbai, India; 2Department of Psychology, University of Toronto, Toronto, ON, Canada; 3Lokmanya Tilak...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amresh Shrivastava, Megan E Johnston, Nilesh Shah, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/f9ec984955e64d6c8fb19cfe08985702
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f9ec984955e64d6c8fb19cfe08985702
record_format	dspace
spelling	oai:doaj.org-article:f9ec984955e64d6c8fb19cfe089857022021-12-02T01:14:04ZPersistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension1176-63281178-2021https://doaj.org/article/f9ec984955e64d6c8fb19cfe089857022010-09-01T00:00:00Zhttp://www.dovepress.com/persistent-suicide-risk-in-clinically-improved-schizophrenia-patients--a5349https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Amresh Shrivastava1, Megan E Johnston2, Nilesh Shah3, Marco Innamorati4, Larry Stitt5, Meghana Thakar3, David Lester6, Maurizio Pompili4,71Silver Mind Hospital and Mental Health Foundation of India, Mumbai, India; 2Department of Psychology, University of Toronto, Toronto, ON, Canada; 3Lokmanya Tilak Municipal General Hospital, University of Mumbai, India; 4Department of Neurosciences, Mental Health and Sensory Functions, Suicide Prevention Center, Sant&rsquo;Andrea Hospital, Sapienza University of Rome, Rome, Italy; 5Department of Biostatistics, The University of Western Ontario, London, ON, Canada; 6The Richard Stockton College of New Jersey, Pomona, NJ, USA; 7McLean Hospital, Harvard Medical School, Boston, MA, USABackground: Suicide is a major problem in schizophrenia, estimated to affect 9%&ndash;13% of patients. About 25% of schizophrenic patients make at least one suicide attempt in their lifetime. Current outcome measures do not address this problem, even though it affects quality of life and patient safety. The aim of this study was to assess suicidality in long-term clinically improved schizophrenia patients who were treated in a nongovernmental psychiatric treatment centre in Mumbai, India.Method: Participants were 61 patients out of 200 consecutive hospitalized first-episode patients with schizophrenia diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders who were much improved on the Clinical Global Impression Scale-Improvement (CGI-I) scale at the endpoint of a 10-year follow-up. Clinical assessment tools included the Positive and Negative Syndrome Scale for Schizophrenia, CGI-I, Global Assessment of Functioning, and suicidality.Results: Many of the patients, although clinically improved, experienced emerging suicidality during the 10-year follow-up period. All of the patients reported significant suicidality (ie, suicide attempts, suicidal crises, or suicidal ideation) at the end of the study, whereas only 83% had reported previous significant suicidality at baseline. No sociodemographic and clinical variables at baseline were predictive of suicidal status at the end of the 10-year follow-up.Conclusion: Schizophrenia is a complex neurobehavioral disorder that appears to be closely associated with suicidal behavior. Adequate assessment and management of suicidality needs to be a continual process, even in patients who respond well to treatment.Keywords: schizophrenia, suicide risk, prevention&nbsp; Amresh ShrivastavaMegan E JohnstonNilesh Shahet alDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 633-638 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Amresh Shrivastava Megan E Johnston Nilesh Shah et al Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension
description	Amresh Shrivastava1, Megan E Johnston2, Nilesh Shah3, Marco Innamorati4, Larry Stitt5, Meghana Thakar3, David Lester6, Maurizio Pompili4,71Silver Mind Hospital and Mental Health Foundation of India, Mumbai, India; 2Department of Psychology, University of Toronto, Toronto, ON, Canada; 3Lokmanya Tilak Municipal General Hospital, University of Mumbai, India; 4Department of Neurosciences, Mental Health and Sensory Functions, Suicide Prevention Center, Sant&rsquo;Andrea Hospital, Sapienza University of Rome, Rome, Italy; 5Department of Biostatistics, The University of Western Ontario, London, ON, Canada; 6The Richard Stockton College of New Jersey, Pomona, NJ, USA; 7McLean Hospital, Harvard Medical School, Boston, MA, USABackground: Suicide is a major problem in schizophrenia, estimated to affect 9%&ndash;13% of patients. About 25% of schizophrenic patients make at least one suicide attempt in their lifetime. Current outcome measures do not address this problem, even though it affects quality of life and patient safety. The aim of this study was to assess suicidality in long-term clinically improved schizophrenia patients who were treated in a nongovernmental psychiatric treatment centre in Mumbai, India.Method: Participants were 61 patients out of 200 consecutive hospitalized first-episode patients with schizophrenia diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders who were much improved on the Clinical Global Impression Scale-Improvement (CGI-I) scale at the endpoint of a 10-year follow-up. Clinical assessment tools included the Positive and Negative Syndrome Scale for Schizophrenia, CGI-I, Global Assessment of Functioning, and suicidality.Results: Many of the patients, although clinically improved, experienced emerging suicidality during the 10-year follow-up period. All of the patients reported significant suicidality (ie, suicide attempts, suicidal crises, or suicidal ideation) at the end of the study, whereas only 83% had reported previous significant suicidality at baseline. No sociodemographic and clinical variables at baseline were predictive of suicidal status at the end of the 10-year follow-up.Conclusion: Schizophrenia is a complex neurobehavioral disorder that appears to be closely associated with suicidal behavior. Adequate assessment and management of suicidality needs to be a continual process, even in patients who respond well to treatment.Keywords: schizophrenia, suicide risk, prevention&nbsp;
format	article
author	Amresh Shrivastava Megan E Johnston Nilesh Shah et al
author_facet	Amresh Shrivastava Megan E Johnston Nilesh Shah et al
author_sort	Amresh Shrivastava
title	Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension
title_short	Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension
title_full	Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension
title_fullStr	Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension
title_full_unstemmed	Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension
title_sort	persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/f9ec984955e64d6c8fb19cfe08985702
work_keys_str_mv	AT amreshshrivastava persistentsuicideriskinclinicallyimprovedschizophreniapatientschallengeofthesuicidaldimension AT meganejohnston persistentsuicideriskinclinicallyimprovedschizophreniapatientschallengeofthesuicidaldimension AT nileshshah persistentsuicideriskinclinicallyimprovedschizophreniapatientschallengeofthesuicidaldimension AT etal persistentsuicideriskinclinicallyimprovedschizophreniapatientschallengeofthesuicidaldimension
_version_	1718403233540472832

Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension

Ejemplares similares